Penpulimab plus chemotherapy significantly improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma
New drug plus chemo delays cancer growth in advanced nasopharyngeal cases
This randomized, double-blind phase 3 trial evaluated penpulimab combined with cisplatin/carboplatin and gemcitabine versus placebo plus che…
Adding penpulimab to chemotherapy delays cancer growth by nearly three months in advanced nasopharyngeal cases, offering new hope for patien…
Becotatug vedotin shows antitumor activity in pretreated recurrent or metastatic nasopharyngeal carcinoma
A New Drug Shows Promise for Tough-to-Treat Nasopharyngeal Cancer
A phase IIa single-arm trial of 61 patients with platinum-refractory recurrent or metastatic nasopharyngeal carcinoma found an objective res…
For patients with a hard-to-treat head and neck cancer who have few treatments left, a new experimental therapy is showing encouraging resul…
Research across Head and Neck Cancer
Related studies from across the Head and Neck Cancer family.
Genetic Markers and EBV Strains Influence Nasopharyngeal Carcinoma Risk in East Asian Populations
High-Risk EBV Strain Tied to Nasopharyngeal Cancer Risk
A meta-analysis identifies a significant 30.9-fold risk increase for nasopharyngeal carcinoma in patients with specific EBV strains and lack…
Certain Epstein-Barr virus strains may account for most nasopharyngeal carcinoma risk in East and Southeast Asia, a genetic analysis suggest…
Induction TPF chemotherapy followed by concurrent chemoradiotherapy shows no significant difference in 3-year progression-free survival
Trial shows TPF chemotherapy impacts side effects for nasopharyngeal cancer
This Phase III randomized controlled trial of 266 patients with locally advanced nasopharyngeal carcinoma found no significant difference in…
A Phase III trial found that a specific chemotherapy sequence reduced some radiation side effects but increased risks of blood cell issues.
PD-1/PD-L1 inhibitors with anti-angiogenic drugs achieve 48% ORR in recurrent or metastatic nasopharyngeal carcinoma
New drug combinations show promise for advanced nasopharyngeal cancer
This meta-analysis of 10 independent cohorts from 9 studies evaluates PD-1/PD-L1 inhibitors combined with small-molecule anti-angiogenic dru…
Combining certain immunotherapy drugs with anti-angiogenic agents shows a 48% response rate for patients with advanced nasopharyngeal cancer…
Elevated serum uric acid levels correlate with improved overall survival in nasopharyngeal carcinoma
High uric acid levels may improve survival in nasopharyngeal cancer
This meta-analysis of observational data indicates that elevated serum uric acid (SUA) levels are significantly associated with improved ove…
New data suggests that higher levels of uric acid in the blood could be a useful sign for predicting survival in patients with nasopharyngea…
Radiotherapy for nasopharyngeal carcinoma is associated with a significant increased risk of otitis media with effusion
Radiotherapy for nasopharyngeal cancer increases risk of middle ear fluid
This meta-analysis of 582 patients indicates that radiotherapy for nasopharyngeal carcinoma is associated with a significant increase in oti…
Patients undergoing radiotherapy for nasopharyngeal cancer face a higher risk of developing fluid in the middle ear, a common side effect of…
Immune cell-based therapy shows no significant benefits for tumor response or survival in HNSCC trials
Immune cell therapy shows limited promise for head and neck cancer
This meta-analysis of 30 trials involving 953 patients evaluated immune cell-based therapy (ICT) for head and neck squamous cell carcinoma. …
New data on immune cell-based therapies for head and neck cancer shows mixed results and a need for more rigorous testing.
Volumetric inaccuracies in nasopharyngeal carcinoma primary tumor segmentation may reduce tumor control probability
Improved Segmentation Accuracy May Improve Treatment for Nasopharyngeal Carcinoma
This guideline-based study evaluates the impact of anatomical and volumetric accuracy on CTVp consistency and dosimetric parameters in nasop…
New analysis shows that accurate volume measurements for nasopharyngeal tumors are key to improving treatment plans and patient outcomes.
Paclitaxel and Cisplatin Combination Improves Outcomes in Locoregionally Advanced Nasopharyngeal Carcinoma
Trial shows TPC chemotherapy improves survival for nasopharyngeal carcinoma
A randomized trial demonstrates that TPC induction chemotherapy significantly improves failure-free survival for patients with high-risk nas…
A new clinical trial found that a specific three-drug induction chemotherapy may improve survival rates for patients with high-risk nasophar…
Primary endoscopic nasopharyngectomy achieves 90.6% five-year overall survival across all tumor stages in nasopharyngeal carcinoma
Endoscopic Surgery Shows Promise for Early Stage Nasopharyngeal Cancer
This systematic review and meta-analysis of 164 patients found that primary endoscopic nasopharyngectomy (pENPG) achieved a 90.6% five-year …
A review of surgical outcomes suggests endoscopic surgery may offer a way to treat early-stage nasopharyngeal cancer while reducing radiatio…
Anti-PD-1 based chemo-immunotherapy for nasopharyngeal carcinoma yields objective response rates of 20 to 91 percent
New Research Explores Treatments for Nasopharyngeal Carcinoma
This narrative synthesis reviews 182 studies regarding the mechanisms and treatments for nasopharyngeal carcinoma. It highlights that anti-P…
New research explores how immunotherapy and targeted treatments can improve outcomes for patients with nasopharyngeal carcinoma.
PD-1 inhibitors plus chemotherapy achieve 64% objective response rate in recurrent or metastatic nasopharyngeal carcinoma
Different PD-1 Inhibitors Show Varying Results for Nasopharyngeal Cancer
This systematic review and meta-analysis of 1,459 patients with recurrent or metastatic nasopharyngeal carcinoma found a pooled objective re…
A review of 1,459 patients shows that different PD-1 inhibitors combined with chemotherapy offer varying survival and response rates for nas…
Immune checkpoint blockade shows promise but faces resistance challenges in nasopharyngeal carcinoma
Immune checkpoint blockade may help treat nasopharyngeal carcinoma
This narrative review examines immune checkpoint blockade in nasopharyngeal carcinoma. It highlights that while 5-year overall survival for …
A narrative review suggests immune checkpoint blockade could guide new treatments for nasopharyngeal carcinoma, though resistance remains a …